Obesity has been associated with inferior outcomes in early-stage breast cancer, but its clinical relevance in metastatic disease treated with CDK4/6 inhibitors remains uncertain. We retrospectively analyzed 332 patients with hormone receptor-positive/HER2-negative metastatic breast cancer who received first-line ribociclib or palbociclib plus endocrine therapy between 2018 and 2023. Patients were stratified by baseline BMI: <30 kg/m 2 ( n = 221) and ≥ 30 kg/m 2 ( n = 111). Survival outcomes were estimated using Kaplan–Meier and Cox models, and treatment-related adverse events were compared between the groups. The median follow-up duration was 23.1 months. The median PFS was significantly longer in patients with a BMI ≥ 30 kg/m 2 than in those with a BMI < 30 kg/m 2 (46.5 vs. 23.8 months; p = 0.016). In multivariate analysis, BMI ≥ 30 kg/m 2 remained significantly associated with longer PFS (HR, 0.679; 95% CI, 0.468–0.985; p = 0.041). The median OS was not reached in either group. Patients with a BMI ≥ 30 kg/m 2 experienced lower rates of any-grade toxicity and dose-reducing TRAEs. These findings suggest a potential association between BMI and clinical outcomes in this treatment setting. Prospective studies that integrate body composition and pharmacokinetics are required for validation.
Günaltılı et al. (Tue,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: